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Reciprocal Catecholamine Changes during Opiate Exposure
and Withdrawal
Megan E Fox1, Nathan T Rodeberg1 and R Mark Wightman*,1
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Dysregulated catecholamine signaling has long been implicated in drug abuse. Although much is known about adaptations following
chronic drug administration, little work has investigated how a single drug exposure paired with withdrawal influences catecholamine
signaling in vivo. We used fast-scan cyclic voltammetry in freely moving rats to measure real-time catecholamine overflow during acute
morphine exposure and naloxone-precipitated withdrawal in two regions associated with the addiction cycle: the dopamine-dense nucleus
accumbens (NAc) and norepinephrine-rich ventral bed nucleus of the stria terminalis (vBNST). We compared dopamine transients in the
NAc with norepinephrine concentration changes in the vBNST, and correlated release with specific withdrawal-related behaviors.
Morphine increased dopamine transients in the NAc, but did not elicit norepinephrine responses in the vBNST. Conversely, dopamine
output was decreased during withdrawal, while norepinephrine was released in the vBNST during specific withdrawal symptoms. Both
norepinephrine and withdrawal symptoms could be elicited in the absence of morphine by administering naloxone with an α2 antagonist.
The data support reciprocal roles for dopamine and norepinephrine signaling during drug exposure and withdrawal. The data also support
the allostasis model and show that negative-reinforcement may begin working after a single exposure/withdrawal episode.
Neuropsychopharmacology (2017) 42, 671–681; doi:10.1038/npp.2016.135; published online 17 August 2016
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INTRODUCTION
Drug exposure causes lasting neural adaptations that increase
the risk for relapse long after drug cessation (Nestler, 2001),
and considerable evidence indicates forebrain catecholamine
circuits become dysregulated during the development of
addiction (Koob and Volkow, 2010). In the allostasis model,
drug abuse develops after a shift from positively to negatively
reinforced drug use, and adaptations in catecholaminergic
signaling may contribute to this phenomenon (Koob and
Volkow, 2010). Drugs of abuse have diverse actions on
dopaminergic signaling in the ventral tegmental area (VTA)
and its afferents (Juarez and Han, 2016), where dopamine is
thought to aid in associative memory formation and drive
cue-induced drug seeking (Berke and Hyman, 2000; Everitt
and Robbins, 2005; Hyman et al, 2006). Action potentials
from the VTA drive transient dopamine concentration
fluctuations in the nucleus accumbens (NAc) (Sombers
et al, 2009) that increase following drug administration and
can potentiate a drug’s positively reinforcing properties
(Covey et al, 2014). However, NAc dopamine may also play
a role in the negatively reinforced component of drug abuse,
since dopamine overflow is suppressed during noxious and
aversive stimuli (Park et al, 2015; Roitman et al, 2008;
Twining et al, 2015). Although basal dopamine levels decrease
during withdrawal (Pothos et al, 1991; Weiss et al, 1996),
previous work does not address its effect on phasic dopamine
concentrations. Bidirectional changes in dopamine signaling
likely contribute to drug use (Koob and Volkow, 2010);
therefore, how dopamine signals during both drug exposure
and withdrawal is an important area of investigation.
Norepinephrine signaling also plays a role in drug reward
(Olson et al, 2006) and withdrawal aversion (Delfs et al,
2000). Suppression of noradrenergic signaling blocks stress-
induced reinstatement (Erb et al, 2000; Leri et al, 2002;
Shaham et al, 2000), and treatment with the adrenergic
agonist clonidine promotes heroin-abstinence in human
addicts (Kowalczyk et al, 2015). Although few studies
emphasize the noradrenergic component of drug use,
norepinephrine in the bed nucleus of the stria terminalis
(BNST) has been clearly implicated in drug withdrawal
(Aston-Jones et al, 1999). The ventral BNST (vBNST) receives
dense innervation from the nucleus of the solitary tract (NTS)
(Forray and Gysling, 2004), the source of norepinephrine
critical for withdrawal aversion (Delfs et al, 2000), and
chronic morphine treatment increases basal norepinephrine
in the BNST (Fuentealba et al, 2000). However, no work
addresses the effect of acute drug exposure or withdrawal on
phasic release. Moreover, stress-dependent adaptations in
vBNST noradrenergic signaling arise following morphine-
dependence (Fox et al, 2015; McElligott et al, 2013), yet the
source of this plasticity is unknown.
Many studies focus on chronic drug administration
(Harris and Aston-Jones, 1994; Hemby et al, 1995;
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Kaufling and Aston-Jones, 2015; Mazei-Robison and Nestler,
2012); however, it is unknown how drug exposure paired
with withdrawal alters catecholamine signaling in regions
associated with the addiction cycle. Since appetitive and
aversive stimuli elicit opposing responses from catechola-
mines (Park et al, 2012; Roitman et al, 2008; Twining et al,
2015), we hypothesized dopamine and norepinephrine signal
reciprocally during drug exposure and withdrawal. We used
voltammetry to measure catecholamine release in freely
moving animals exposed to morphine and naloxone-
precipitated withdrawal. During drug exposure, dopamine
signaling increased in the NAc but morphine did not elicit
norepinephrine in the vBNST. Conversely, drug withdrawal
produced vBNST norepinephrine release that coincided with
specific withdrawal symptoms. Finally, vBNST norepinephr-
ine release, but not NAc dopamine, was attenuated after
treatment. These data provide a real-time view of catecho-
lamine signaling during drug exposure and withdrawal, and
lend insight to how catecholamine circuits may become
dysregulated after drug use.
MATERIALS AND METHODS
Additional details are described in Supplementary Methods.
Animal Care
All experiments were performed in accordance with the
Institutional Animal Care and Use Committee guidelines of
the University of North Carolina at Chapel Hill (UNC).
Sprague-Dawley rats (males, 270–350 g; Charles River,
Wilmington, MA) were given food and water ad libitum
and pair-housed in UNC animal facilities on a 12 : 12-h
light : dark cycle until surgery. Animals with misplaced
electrodes, as well as animals that exhibited mixed pharma-
cological response, were excluded from the study (see
Supplementary Figure S1). A total of 14 animals were
included for dopamine measurements (7 morphine–nalox-
one, 7 vehicle–naloxone), and 29 for norepinephrine
measurements (7 morphine–naloxone, 7 vehicle–naloxone,
6 morphine–naloxone +idazoxan, 6 vehicle–naloxone+ida-
zoxan, 3 spontaneous withdrawal). Two separate groups of
animals were used to examine the acute effects of morphine
on evoked dopamine (n= 4), and idazoxan on dopamine
transients (n= 3). All measurements took place during the
light cycle.
Sterotaxic Surgery
Animals were anesthetized with isofluorane (4% induction,
1.5% maintenance) and affixed in a stereotaxic frame (Kopf
Instruments). The scalp was removed and holes were drilled
to implant guide cannulas in the right hemisphere (BASi,
West Lafayette, IN) above the NAc shell (AP: +1.7 mm, ML:
+0.8 mm) or vBNST (AP: 0 mm, ML: +1.2 mm), referenced
from bregma and based on the atlas of Paxinos and Watson.
An additional guide cannula was implanted in the left
hemisphere for insertion of an Ag/AgCl reference electrode on
the day of recording. A bipolar stimulating electrode (Plastics
One, Roanoke, VA) was targeted to the right VTA/ventral
noradrenergic bundle (VNB; AP − 5.2 mm, ML +1.0,
DV − 8.2 mm), and a dental cement skull-cap was secured
with jeweler’s screws. Animals were subsequently given
300 mg/kg acetaminophen p.o., singly housed and allowed to
recover for 3 days before making measurements. We
monitored animal recovery and did not make measurements
in any animals appearing to be in pain (eg, ruffled fur,
increased irritability).
Voltammetric Catecholamine Measurements
Fast scan cyclic voltammetry measurements of dopamine
and norepinephrine were performed in awake animals as
described previously (Park et al, 2013). Briefly, a fresh
carbon-fiber electrode (~100 μm active length) was lowered
into the NAc shell or vBNST through the guide cannula with
a custom-built micromanipulator. A triangular waveform
(−0.4 to +1.3 V, 400 V/s) was applied to the electrode every
100 ms to oxidize and reduce catecholamines using HDCV
for data acquisition and analysis. After electrode placement,
we recorded baseline signaling for ~ 10 min before giving
10 mg/kg morphine sulfate s.c. (Sigma-Aldrich, St Louis,
MO) or 1 ml/kg vehicle (saline 0.9%). Four hours later, we
administered 1 mg/kg naloxone HCl s.c. (Sigma-Aldrich)
and scored animals for somatic indices of withdrawal
(Schulteis et al, 1999) over 20 min. In a subset of animals,
5 mg/kg idazoxan was given with naloxone to elicit
norepinephrine overflow. One hour after naloxone admin-
istration, animals were anesthetized with urethane (1.5 g/kg),
and the VTA/VNB was electrically stimulated using constant
current isolators (Neurologs, model NL800) to obtain
voltammograms for principal component analysis (PCA)
(Rodeberg et al, 2015). We extracted dopamine currents
using PCA and converted current to concentration using an
averaged in vitro calibration factor (10 nA/μM). Only
dopamine transients 43 times the noise in the traces
obtained by PCA were considered to be dopamine transients,
and we measured increased dopamine transient frequency
during the first hour of morphine administration. In awake
animals, voltammetric peaks for norepinephrine release in
the vBNST were broader than expected. We suspect
contribution from a noradrenergic metabolite during with-
drawal because these features were mimicked in anesthetized
rats with long stimulations, and were eliminated following
Figure 1 Dopamine efflux in the nucleus accumbens (NAc) varies with morphine exposure and withdrawal. (a) Schematic of electrode placement and
experimental timeline. (b) Representative dopamine (DA) transients at baseline, after morphine, and after naloxone. Principal component analysis identified
concentrations marked with asterisks as DA transients. (c) Representative DA transients at baseline, after vehicle, and after naloxone. (d) Transient frequency
and (e) average DA transient concentration under morphine or vehicle and subsequent naloxone. Average frequency and concentration of dopamine
transients at baseline are indicated by the gray dashed lines. (f) Representative evoked [DA] after treatment in morphine–naloxone or vehicle–naloxone
animals and (g) data from all subjects. (h) Representative evoked [DA] in naïve animals at baseline (solid line) and after morphine (hashed line) and (i) data
from all subjects. Bar graphs show average± SEM with individual subjects overlaid. **Po0.01, ***Po0.001, two-way repeated measures ANOVA, Bonferroni
post hoc. +, Po0.05, paired T-test. DS, dorsal striatum.
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inhibition of monoamine oxidase with clorgyline. Norepi-
nephrine currents were extracted with PCA; however, the
extent to which the metabolite component influences in vitro
calibration factors is unknown. For this reason, we report
extracted norepinephrine currents, but not concentration in
awake animals. When applicable, an averaged in vitro
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calibration factor (6 nA/μM) was used to convert norepi-
nephrine current to concentration in anesthetized animals.
vBNST Pharmacology
At the end of awake-animal recordings, we confirmed that
the signal in the vBNST was due to norepinephrine and not
dopamine by measuring evoked release after 2 mg/kg s-(− )-
raclopride tartrate (D2 antagonist; Sigma-Aldrich) and
5 mg/kg idaxoxan HCl (α2 antagonist; Sigma Aldrich). Only
signals that responded to idazoxan but not raclopride
were classified as norepinephrine release. Signals with
mixed pharmacological response were excluded as in
Supplementary Figure S1.
Somatic Withdrawal Signs
Behavioral correlates of opiate withdrawal were measured
during the first 20 min of precipitated withdrawal and
assigned a global withdrawal score as described previously
and in detail in Supplementary Methods (McElligott et al,
2013). We manually assigned time-stamps to each behavior
and looked for the presence or absence of dopamine
transients or norepinephrine overflow during the withdrawal
signs. Somatic withdrawal signs were either considered
absent, present, or present with catecholamine signaling.
Statistics
All statistical tests were performed in Graph Pad Prism.
Two-way, repeated measures analysis of variance (ANOVA)
with Bonferroni post hoc were used to assess differences in
release event frequency and concentration under varying
drug conditions. An unpaired Welch’s corrected t-test was
used to determine significant differences between evoked
norepinephrine concentrations after withdrawal due to
significant differences in the variance between morphine-
and vehicle-treated groups.
RESULTS
Morphine-Exposure Increases Dopaminergic
Transmission in the NAc
Drugs of abuse increase dopaminergic transmission in the
NAc (Cheer et al, 2007; Daberkow et al, 2013; Di Chiara and
Imperato, 1988; Phillips et al, 2003; Volkow et al, 2007),
which contributes to their acutely reinforcing properties. We
used a dose of morphine that, when paired with precipitated
withdrawal, generates rapid dependence in rats (Schulteis
et al, 1999). To confirm that morphine elevates dopamine in
the NAc of freely moving rats (Vander Weele et al, 2014), we
used voltammetry to record dopamine transients in locations
exhibiting spontaneous activity ( ~2 transients per minute;
schematic of placement and time line in Figure 1a,
representative traces and color plots in Figure 1b and c).
We found that morphine increased spontaneous dopamine
transient frequency in the NAc (10 mg/kg s.c.) relative to
saline (vehicle, 1 ml/kg s.c.) (9.9± 1.5 vs 2.1± 0.5 transients
per minute, morphine vs vehicle, N= 7, respectively,
t= 4.976, P= 0.0016; Figure 1d), but the average concentra-
tion per transient was similar under both conditions
(morphine: 77.3± 7 vs vehicle: 72.1± 7 nM, N= 7, respec-
tively; Figure 1e).
Naloxone-Precipitated Withdrawal Decreases
Dopaminergic Transmission in the NAc
We next examined the impact of drug withdrawal by
administering naloxone (1 mg/kg s.c.) 4 h after initial
morphine (Fox et al, 2015; McElligott et al, 2013; Schulteis
et al, 1999). We recorded dopamine transients over 20min
during the peak of somatic withdrawal signs and found
dopamine transient frequency decreased in animals under-
going withdrawal relative to initial treatment (9.9± 1.5 vs
2.3± 0.5 transients per minute, morphine vs morphine–
naloxone; 2.1± 0.5 vs 1.1± 0.1 transients per minute, vehicle
vs vehicle–naloxone, N= 7, respectively; Figure 1d). Post hoc
analysis revealed a significant decrease in dopamine transient
frequency between morphine and morphine–naloxone (two-
way repeated measures ANOVA, morphine treatment
group×naloxone interaction F(1,12)= 22.60, P= 0.0005; mor-
phine treatment F(1,12)= 23.06, P= 0.0004; naloxone treat-
ment F(1,12)= 40.30, Po0.0001, Bonferroni post hoc,
Po0.001) but not between vehicle and vehicle–naloxone
(P40.05). Moreover, average dopamine transient concentra-
tions decreased during withdrawal that was not solely due to
naloxone (morphine–naloxone: 57.6± 4 vs vehicle–naloxone:
71.9± 8 nM, N= 7, respectively. Two-way repeated measures
ANOVA; morphine treatment group×naloxone interaction
F(1,12)= 9.667, P= 0.0090, naloxone F(1,12)= 10.3, P= 0.0075,
Bonferonni post hoc, Po0.01; Figure 1e), reflecting decreased
dopaminergic output in the drug-withdrawn group. To
determine if decreased dopamine concentrations in mor-
phine–naloxone animals were due to adaptations in releasable
dopamine, we anesthetized the animals after treatment and
electrically stimulated the VTA. We found equivalent evoked
dopamine in morphine–naloxone and vehicle–naloxone-trea-
ted animals (1.28± .37 vs 0.96± 0.31 μM, N= 7, respectively,
t= 0.6634, P= 0.5196; Figure 1f and g). In a separate group of
rats, we assayed the effect of morphine alone on electrically
evoked dopamine release. Morphine increased evoked
dopamine concentrations (baseline vs morphine: 2.9± 1.5 vs
4.4± 0.8 μM, N= 4, P= 0.04, paired T-test; Figure 1h and i).
Acute exposure/withdrawal did not elicit persistent adaptations,
in agreement with our previous study showing dopamine tissue
content is unchanged in the NAc after repeated morphine/
naloxone treatment (McElligott et al, 2013).
Morphine Withdrawal, but not Exposure, Elicits
Norepinephrine in the vBNST
Norepinephrine’s role in drug addiction is often over-
shadowed by dopamine, despite evidence that morphine
reward may be contingent on brainstem norepinephrine
synthesis (Olson et al, 2006). Additionally, opiate-withdrawal
aversion requires forebrain norepinephrine (Delfs et al,
2000), and morphine-dependence alters noradrenergic sy-
naptic function in the vBNST (Fox et al, 2015; McElligott
et al, 2013). We thus measured norepinephrine release in the
vBNST during morphine exposure and withdrawal (sche-
matic in Figure 2a). Unlike dopamine, norepinephrine
concentrations in the vBNST do not fluctuate spontaneously
in animals at rest, and morphine did not elicit
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Figure 2 Naloxone-precipitated withdrawal produces norepinephrine overflow in the ventral bed nucleus of the stria terminalis (vBNST). (a) Schematic of
electrode placement and experimental timeline. (b, c) Representative norepinephrine (NE) response at baseline, after morphine or vehicle, and after naloxone.
NE current is isolated from corresponding color plots using principal component analysis. Asterisk suggests oxidation of metabolite. (d) Total NE release events
during morphine/vehicle and subsequent naloxone. ***Po0.001, two-way repeated measures ANOVA with Bonferroni post hoc. (e) Release amplitude during
morphine/vehicle and subsequent naloxone. Bars are average ± SEM with individual events overlaid. (f) Representative evoked NE after treatment in
morphine–naloxone and vehicle–naloxone animals and (g) data from all subjects. *Po0.05, Welch’s corrected unpaired t-test. DS, dorsal striatum.
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norepinephrine overflow in the vBNST (examples in
Figure 2b and c). However, we observed broad norepinephrine
release events during naloxone-precipitated withdrawal
(eg, Figure 2b, d and e) that did not occur without naloxone
(Supplementary Figure S2). Norepinephrine release persisted
for tens of seconds, in contrast to brief (~1 s) dopamine
transients recorded in the NAc, in a manner similar to
previous studies (Park et al, 2012, 2013). Voltammetric peaks
for norepinephrine were also broader than expected, and we
suspect contribution from a noradrenergic metabolite during
withdrawal (Supplementary Figure S3). Naloxone elicited
norepinephrine release in some vehicle-treated animals;
however, the occurrence of norepinephrine release events
was greater in animals undergoing morphine withdrawal
relative to vehicle–naloxone animals (morphine–naloxone:
3.0± 0.5 vs vehicle–naloxone: 0.4± 0.2 events per animal,
N= 7, respectively; two-way repeated measures ANOVA:
morphine-treatment group F(1,12)= 11.57, treatment group ×
naloxone interaction F(1,12)= 11.57, naloxone F(1,12)= 20.25,
Bonferroni post hoc, Po0.001; Figure 2d). Norepinephrine
release amplitudes did not differ between groups (morphine-
naloxone: 1.1± 0.1 nA, N= 21 events vs vehicle-naloxone:
1.7± 0.5 nA N= 3 events; Figure 2e). We next assayed
releasable norepinephrine by electrically stimulating the
VNB and found significant attenuation in morphine
withdrawn animals (0.047± 0.011 vs 0.218± 0.053 μM, N= 7;
t= 3.115, P= 0.0207; Figure 2f and g). This finding aligns with
our previous study demonstrating reduced norepinephrine
tissue content after repeated naloxone-precipitated withdrawal
(McElligott et al, 2013). Moreover, this was not an effect
of morphine alone, as morphine does not alter evoked
norepinephrine in anesthetized animals (McElligott et al,
2013), and animals that underwent spontaneous withdrawal
(without naloxone) had similar release compared to vehicle-
naloxone animals (Supplementary Figure S2).
Catecholamine Signaling Differs During Expression of
Withdrawal-Related Behaviors
Somatic withdrawal signs like teeth-chattering and eye-
twitches are a hallmark of opiate withdrawal in rats
(Schulteis et al, 1999). Naloxone treatment produced somatic
withdrawal behaviors and global withdrawal scores similar to
our previous reports (Fox et al, 2015; McElligott et al, 2013),
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Figure 3 Somatic withdrawal signs produce variable catecholamine release in the nucleus accumbens (NAc) and ventral bed nucleus of the stria terminalis
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and scores were significantly higher in morphine-withdrawn
animals (Supplementary Figure S5, two-way ANOVA,
Bonferroni Post hoc: main effect of morphine F(1,12)
= 57.65, Po0.0001. DA: morphine–naloxone, 5.7± 1.0 vs
vehicle–naloxone, 2.0± 0.5; NE: morphine–naloxone,
7.2± 0.5 vs vehicle–naloxone, 1.0± 0.4 N= 7, respectively).
To determine if catecholamine overflow was associated with
withdrawal symptoms, we recorded the timing of somatic
withdrawal behaviors and looked for concurrent dopamine
or norepinephrine release. Morphine withdrawal normalized
the frequency of dopamine transients, and in some cases,
transients appeared to pause during certain behaviors (eg,
swallowing movements, SM; example in Figure 3a). This
effect varied between subjects (example of teeth chattering,
TC; Figure 3b). Dopamine release was loosely associated with
spontaneous erection/ejaculation/penile grooming (EEP) in
the three animals exhibiting the behavior (example in
Figure 3c).
Norepinephrine release occurred with SM and TC in
morphine-withdrawn animals (examples in Figure 3d and e),
and in one vehicle-naloxone animal, but not during EEP
(example in Figure 3f). When we compared the incidence of
somatic withdrawal behaviors with catecholamine release, we
found that every TC or SM occurred with norepinephrine
release (Figure 4a), but was not time-locked to dopamine
transients (Figure 4b). For this reason, we chose to further
investigate the link between somatic withdrawal behaviors of
TC/SM and norepinephrine release. We compared the
duration of norepinephrine overflow with the duration of
TC and SM and found a linear relationship between TC/SM
duration and norepinephrine release (slope: 0.88± 0.05,
r2= 0.95; Figure 4c), that is, when SM initiated, we measured
increased norepinephrine; when SM terminated, so did the
norepinephrine signal. We next compared the total duration
of norepinephrine release in individual subjects vs their
global withdrawal scores and found a linear correlation
(slope: 5.8± 0.9, r2= 0.76; Figure 4d).
Systemic α2 Antagonism with Naloxone Produced
Withdrawal Signs and Norepinephrine in the Absence of
Morphine
To strengthen the relationship between norepinephrine over-
flow and TC/SM, we next administered the α2 antagonist
idazoxan with naloxone to elicit norepinephrine overflow in
drug-naïve animals (example in Figure 5a). Systemic α2
antagonism elicited norepinephrine in vehicle–naloxone
animals, and did not significantly alter the magnitude of
norepinephrine release in animals given idazoxan during
naloxone-precipitated morphine withdrawal (example in
Figure 5b and all data in Figure 5c). Accompanying
norepinephrine release in vehicle–naloxone/idazoxan-treated
animals were increased withdrawal signs (Figure 5d) and
global withdrawal scores (Figure 5e). When we compared total
norepinephrine duration with global withdrawal scores, there
was not a strong linear relationship (slope: 25.0± 2.5, r2= 0.31;
Figure 5f). However, when we compared the duration of
overflow only in vehicle–naloxone/idazoxan animals, we
found a linear correlation (slope: 66.6± 16.5, r2= 0.80).
Finally, to test the effects of increased norepinephrine on
dopamine in the NAc, we administered idazoxan to a subset
of animals and recorded changes in dopamine transient
concentrations. Idazoxan did not alter the frequency of
dopamine transients, but decreased the average magnitude
compared with baseline and vehicle (baseline:73.7± 3.6,
vehicle: 68.1± 5.7, idazoxan: 43.0± 1.3 nM, one-way
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the ventral bed nucleus of the stria terminalis (vBNST). (b) Heat map
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repeated measures ANOVA, F(2,8)= 43.13, P= 0.0020, Bon-
ferroni post hoc, Po0.01; Supplementary Figure S4), similar
to the effects of naloxone-precipitated withdrawal.
DISCUSSION
These findings establish that a single exposure to morphine,
followed by precipitated withdrawal, elicits distinct signaling
in two forebrain catecholamine circuits. Dopaminergic
signaling increased in the NAc during morphine exposure
and decreased during withdrawal, but the single exposure
did not cause persistent adaptations. Conversely, only
precipitated withdrawal elicited norepinephrine release in
the vBNST, and this treatment attenuated releasable
norepinephrine. Norepinephrine release tracked two
withdrawal-associated behaviors and both norepinephrine
and withdrawal behaviors were induced without morphine
by α2 antagonism. The combination of decreased dopamine
output and recruitment of noradrenergic signaling revealed
in this work suggests the negative reinforcement model of
drug use may develop after the first drug exposure and
withdrawal episode.
Drugs of abuse increase dopamine overflow in the NAc
(Covey et al, 2014), which helps drive their acutely reinforcing
properties, and a recent study showed intravenous morphine
administration produces similar efflux (Vander Weele et al,
2014). We gave morphine s.c. since i.v. catheters require
rats to be singly housed and social-isolation produces a
stress profile and noradrenergic dysregulation similar to
morphine-dependent rats (Fox et al, 2015). We found
dopamine transients increased in frequency for a much
longer duration (460 min) than in Vander Weele et al
(2014), which could arise due to differences in baseline stress
or the slower time course of drugs delivered s.c. compared
with i.v. This dose of morphine produced immobility in rats,
aligning with a previous study showing morphine increased
immobility and catalepsy similar to the timing of elevated
basal dopamine in the NAc (Sustkova-Fiserova et al, 2014).
After drug administration, animals undergo spontaneous
withdrawal dependent on the half-life of the drug. To
provide a more distinct time point, we precipitated opiate
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withdrawal with naloxone (Schulteis et al, 1999). Naloxone
treatment lowered the frequency of dopamine transients to
that of baseline/vehicle; however, the average concentration
per transient decreased in the drug-withdrawn group. This
effect was not solely due to naloxone, because average
transient concentrations only decreased in animals exposed
to morphine. Furthermore, in some cases dopamine
transients appeared to ‘pause’ during somatic withdrawal
signs. The decrease in dopamine transients during naloxone
agrees with studies showing reduced basal dopamine during
withdrawal (Pothos et al, 1991; Weiss et al, 1996), and aligns
with previous work showing activation of D2 receptors in the
NAc attenuates withdrawal symptoms (Harris and Aston-
Jones, 1994). Decreased dopaminergic output supports the
allostasis model (Koob and Volkow, 2010) and likely
contributes to the withdrawal-induced negative effect.
The role of norepinephrine in drug addiction is often
overshadowed by that of dopamine (Weinshenker and
Schroeder, 2007), despite evidence that medullary norepi-
nephrine synthesis may be crucial for establishing morphine
self-administration (Davis et al, 1975) and conditioned place
preference (Olson et al, 2006). The vBNST receives dense
noradrenergic projections from the NTS (Forray and
Gysling, 2004), and thus is a likely downstream target for
norepinephrine’s actions in morphine reward. However, we
did not detect norepinephrine release in the vBNST during
morphine, although elevated norepinephrine in the BNST
may develop following chronic drug exposure (Fuentealba
et al, 2000). Alternatively, NTS norepinephrine may instead
modulate drug-reward through its projections to the NAc
(Delfs et al, 1998) where it can regulate dopamine efflux, and
presumably the rewarding property of abused drugs through
α1 receptors (Mitrano et al, 2012). Norepinephrine signaling
is traditionally implicated in the aversive aspects of opiate-
withdrawal (Aston-Jones et al, 1999). Indeed, direct infusion
of adrenergic antagonists into the BNST suppresses stress-
induced reinstatement of drug seeking and conditioned place
preference (Leri et al, 2002; Wang et al, 2001), and 3 days of
morphine withdrawal produces elevated anxiety and nora-
drenergic plasticity in the vBNST (McElligott et al, 2013).
In agreement with its role in opiate withdrawal, we found
robust norepinephrine release in the vBNST that coincided
with somatic withdrawal behaviors. In particular, norepi-
nephrine was linked with SM and the neurons responsible
for this reflex are located in the NTS (Kessler and Jean,
1985). Interestingly, releasable norepinephrine concentra-
tions were depleted after withdrawal, reflecting signaling
adaptations after the first withdrawal episode. This effect is
consistent with previous work showing reduced norepi-
nephrine tissue content in the vBNST after repeated
morphine withdrawal (McElligott et al, 2013). We also
found norepinephrine release in some vehicle–naloxone-
treated animals. We believe this to be a result of removing
endogenous opiate tone, as withdrawal signs were also noted
in some vehicle–naloxone animals (Figure 4a). The occur-
rence of release events and withdrawal signs was much
greater in animals undergoing withdrawal relative to control,
and evoked release was blunted only in animals that
underwent precipitated withdrawal. Additionally, when we
administered the α2 antagonist idazoxan with naloxone, both
norepinephrine overflow and withdrawal behaviors were
elicited in the absence of morphine, further supporting
norepinephrine’s role in withdrawal aversion. Although we
found a strong link between norepinephrine and TC/SM,
other signaling mechanisms are likely involved in the
expression of somatic withdrawal behaviors. For example,
blockade of mineralocorticoid receptors markedly attenuates
EEP and ptosis (Navarro-Zaragoza et al, 2014), and
inhibition of endocannabinoid catabolic enzymes attenuates
wet dog shakes (Ramesh et al, 2013). Overall, our data
support links between norepinephrine overflow and TC/SM
as well as global withdrawal score, and provide mechanistic
insight for adrenergic receptor therapy in treating human
addicts (Kowalczyk et al, 2015). Moreover, the norepinephr-
ine release during withdrawal uncovered here is the likely
origin of adrenergic receptor plasticity in the vBNST
(McElligott et al, 2013).
Dopamine and norepinephrine exhibit opposing responses
to rewarding and aversive stimuli. Oral infusion of an
appetitive tastant produces enhanced dopamine, whereas
aversive tastants such as quinine suppress dopamine trans-
ients and increase norepinephrine signaling (Park et al, 2012;
Roitman et al, 2008). This effect is also seen in animals
undergoing reward learning and its extinction (Park et al,
2013), and during presentation of a painful stimulus (Park
et al, 2015). Reciprocal catecholamine signaling has interest-
ing implications in the context of the aversive stimulus of
drug withdrawal, due to norepinephrine’s possible influence
on dopaminergic signaling. Glutamatergic inputs from the
vBNST exert strong excitatory influence over VTA dopamine
neurons (Georges and Aston-Jones, 2002), and norepine-
phrine’s actions through α2A receptors decrease excitatory
transmission in the vBNST (Egli et al, 2004). Moreover,
during acute opiate withdrawal, norepinephrine can act
through β-receptors to increase GABAA inhibition of VTA-
projecting BNST neurons (Dumont and Williams, 2004),
leading to increased inhibition of the VTA. Activation of β2-
adrenergic receptors in the vBNST drives stress-induced
reinstatement by releasing CRF in the VTA (Vranjkovic et al,
2014). Although increased VTA CRF can potentiate activity
(Ungless et al, 2003), CRF receptor antagonism in the VTA
blocks the decrease in NAc dopamine transients caused by
aversive quinine infusions (Twining et al, 2015). In this study,
we found decreased dopamine concentrations in the NAc
during withdrawal. This suppression of dopamine concentra-
tions was further mimicked by elevating norepinephrine with
α2 antagonism. Thus, when animals underwent withdrawal,
elevated norepinephrine concentrations in the vBNST may
have suppressed VTA activity, thereby reducing dopamine
transient concentrations in the NAc. At the end of the
treatment, the suppression was relieved: regardless of an
animal’s exposure to withdrawal, direct stimulation of the
VTA resulted in equivalent dopamine release, similar to
tissue-content findings (McElligott et al, 2013). The reciprocal
actions of dopamine and norepinephrine we report during
drug exposure and withdrawal may reflect important feed-
back between catecholamine circuits during rewarding and
aversive stimuli.
Overall, the increased dopaminergic signaling we observed
during morphine exposure supports a rich literature on
dopamine’s role in the rewarding properties of drugs.
Additionally, the enhanced noradrenergic overflow concur-
rent with withdrawal signs underscores norepinephrine’s
importance in mediating opiate-withdrawal aversion. The
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combination of decreased dopaminergic output and en-
hanced noradrenergic overflow revealed in this work
supports the allostasis model, and suggest that negative
reinforcement may emerge after the first exposure/with-
drawal episode. Taken together, this real-time view of
reciprocal catecholamine signaling provides insight as to
how catecholamine circuits in the ventral forebrain may
become dysregulated after drug exposure and withdrawal.
These adaptations may converge with stress or other risk
factors to drive the development of addiction in susceptible
individuals, and how they progress longitudinally should be a
topic of future investigations.
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